Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? (Q37602710)

21 August 2017

1 reference

title

Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? (English)

1 reference

World Health Organization

21 August 2017

main subject

0 references

Klaus Jung

8

1 reference

ORCID Public Data File 2021

author name string

Carsten Stephan

1

1 reference

21 August 2017

Thomas Köpke

2

1 reference

21 August 2017

Axel Semjonow

3

1 reference

21 August 2017

Michael Lein

4

1 reference

21 August 2017

Serdar Deger

5

1 reference

21 August 2017

Mark Schrader

6

1 reference

21 August 2017

Kurt Miller

7

1 reference

21 August 2017

language of work or name

1 reference

1 January 2009

1 reference

Clinical Chemistry and Laboratory Medicine

21 August 2017

published in

1 reference

21 August 2017

volume

47

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1325-1331

1 reference

Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

The clinical impact of different assays for prostate specific antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Prostate specific antigen assay standardization bias could affect clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/CCLM.2009.285

21 January 2018

Identifiers

DOI

10.1515/CCLM.2009.285

1 reference

21 August 2017

1 reference